MED Medifast, Inc.

HRL is using pricing, mix, efficiency and cost discipline to improve profitability as value-focused consumers reshape demand.

HRL's protein portfolio is gaining momentum as brands meet demand for affordable, convenient and versatile food choices.

SAM's innovation, brand investments and productivity efforts aim to drive growth and margin expansion as demand remains challenging.

STZ's premium portfolio and beer leadership continue to fuel growth as it doubles down on innovation and premiumization.

Here is how Laird Superfood, Inc. (LSF) and Medifast (MED) have performed compared to their sector so far this year.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

Monster Beverage's international sales surge in Q2 as growth in China, India and Brazil broadens its overseas engine despite margin pressures.

CLX's margin management, innovation and IGNITE strategy support growth, while cost pressures and value-conscious consumers challenge its progress.

CL is betting on premium innovation, higher ad spending and targeted pricing to revive North America growth after a weak second quarter.

Mission Produce's Q3 revenues climb as avocado volumes surge, but lower pricing squeezes margins while Calavo boosts distribution results.

STZ's premium strategy, strong beer portfolio and brand investments position it for market share gains and long-term growth.

MED is shifting toward metabolic health with its 3.0 strategy, targeting broader growth, greater efficiency and a return to profitability.

BellRing Brands (BRBR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Medifast (MED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

MED's Trilivy launch marks a major metabolic-health shift, backed by a 10-year roadmap and growing GLP-1 market focus.

Medifast (MED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

BUD is premiumizing its portfolio, expanding no-alcohol and Beyond Beer offerings, and scaling digital platforms to drive growth.

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

Medifast trades at $11.62 per share and has stayed right on track with the overall market, gaining 9.6% over the last six months. At the same time, the S&P 500 has returned 12.7%.

MED is reshaping its coach network around Executive Directors as productivity rises despite a sharp decline in active earning coaches.

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

KVUE's Q2 sales and earnings miss estimates, but organic growth improved as Skin Health and Beauty led a broader recovery.

MED's improving coach productivity and client retention point to stabilization, but a shrinking coach base remains a challenge.

Medifast’s second quarter was marked by stabilization in key business metrics despite continued pressure from declining coach numbers and shifting industry trends. The company’s revenue and earnings surpassed Wall Street expectations, contributing to a strong positive market reaction. Management credited improved coach productivity—up for the third consecutive quarter—and the early impact of its new consumer brand, Trilivy, as key drivers of sequential stabilization. CEO Nick Johnson highlighted

DOLE's Q2 earnings miss estimates as higher fruit sourcing, fuel and shipping costs pressured Fresh Fruit, despite strong Americas growth.

Coach count plummeted 48.7%, yet management targets profitability by Q4 2026.

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.

Medifast's Trilivy launch and cost cuts could support a Q4 profit turnaround, but shrinking revenue and its coach base keep risks high.

Medifast stock gains 13.6% in a month as improving coach productivity and earnings expectations support momentum despite weaker revenue.

Medifast's low valuation and improving coach productivity offer potential, but a shrinking coach base and weak growth keep the turnaround high risk.

PRMB beats second-quarter earnings and sales estimates, fueled by spring and premium water, and raises its 2026 sales growth outlook.

ADM adjusted earnings nearly double in the second quarter as oilseeds, ethanol and Nutrition gains fuel a raised 2026 outlook.

MED tops Q2 earnings expectations despite lower sales, as rising coach productivity helps offset pressure from a shrinking coach network.

Moby summary of Medifast, Inc.'s Q2 2026 earnings call

Medifast Inc (MED) navigates a 27.6% revenue drop while boosting coach productivity 41% and launching its Trilivy brand to target metabolic health and return to profitability by Q4 2026.

Medifast (NYSE:MED) reported second-quarter 2026 revenue of $76.4 million, down 27.6% from a year earlier, as its active earning coach base continued to decline amid the rapid adoption of GLP-1 medications across the traditional weight-loss category. The company posted a net loss of $3.1 million, or

Medifast (MED) delivered earnings and revenue surprises of +58.21% and +1.14%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Wellness company Medifast (NYSE:MED) reported Q2 CY2026 results topping the market’s revenue expectations, but sales fell by 27.6% year on year to $76.38 million. On top of that, next quarter’s revenue guidance ($70 million at the midpoint) was surprisingly good and 3.4% above what analysts were expecting. Its GAAP loss of $0.28 per share was 56.9% above analysts’ consensus estimates.

Wellness company Medifast (NYSE:MED) will be reporting results this Monday after market hours. Here’s what you need to know.

CL's Q2 earnings beat as organic sales, productivity and margin gains offset higher brand investment, while Latin America led regional growth.

PG's Q4 earnings beat estimates as productivity savings offset cost pressures, while flat organic sales and modest fiscal 2027 guidance temper the outlook.

MED's Q2 results are likely to face continued pressure from GLP-1 adoption and a smaller coach base, while productivity gains and cost actions may have helped offset some challenges.

BellRing Brands (BRBR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Medifast (MED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The past year hasn’t been kind to the stocks featured in this article. Each has tumbled to its lowest point in 12 months, leaving investors to decide whether they’re witnessing fire sales or falling knives.

COCO's strong Q2 beat, higher guidance and the Copra acquisition highlight accelerating momentum in coconut water and private label growth.

POST is repositioning its pet food brands with pricing changes and the Nutrish relaunch to improve volumes and category performance.

KR is simplifying its pricing strategy to strengthen value perception while funding investments through efficiency gains.

TAP is leaning on premium beer, acquisitions and its Horizon 2030 strategy to expand beyond brewing and support long-term growth.